{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:08:19Z","timestamp":1785186499046,"version":"3.55.0"},"reference-count":16,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,6,6]],"date-time":"2012-06-06T00:00:00Z","timestamp":1338940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Objective\u2002<\/jats:bold> The use of ergot\u2010derived dopamine agonists (DA) to treat patients with prolactinomas has not been associated with an increased risk of significant heart valve dysfunction. Accordingly, the present study evaluated whether the long\u2010term use of DA for hyperprolactinaemia may be associated with increased risk of significant valvular heart disease.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> A total of 74 patients (mean age 48\u2003\u00b1\u20031\u00b74\u2003years, 23% male) with prolactinoma treated with DA for at least 1\u2003year were evaluated with 2\u2010dimensional echocardiography at baseline. After 2\u2003years of follow\u2010up, a repeat echocardiography was performed to evaluate significant changes in valvular heart structure (thickening, calcifications and leaflet motion abnormalities) and function (regurgitation or stenosis). Patients were classified according to treatment: patients treated with cabergoline (group 1: <jats:italic>n<\/jats:italic>\u2003=\u200345), and patients not treated with cabergoline (group 2: <jats:italic>n<\/jats:italic>\u2003=\u200329).<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> At 2\u2010year follow\u2010up, no significant valvular stenosis was observed in any patient. In addition, the prevalence of any significant valve regurgitation did not change significantly (from 12% to 15%, <jats:italic>P<\/jats:italic>\u2003=\u2003NS). However, there was a significant increase in the prevalence of valvular calcifications (from 48% to 58%, <jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7004) and, particularly, in the prevalence of aortic valve calcifications (from 39% to 53%, <jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7002). In a per\u2010treatment\u2010based analysis, the group of patients treated with cabergoline had significantly higher prevalence of aortic valve calcification at 2\u2003years follow\u2010up as compared to the group of patients not treated with cabergoline (63%<jats:italic>vs<\/jats:italic> 38%, <jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7016).<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> The long\u2010term therapy with DA (cabergoline) of patients with prolactinoma is associated with an increased prevalence of valvular calcification. However, these structural changes were not accompanied by an increased prevalence of valvular dysfunction.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2011.04326.x","type":"journal-article","created":{"date-parts":[[2011,12,25]],"date-time":"2011-12-25T00:10:49Z","timestamp":1324771849000},"page":"99-105","source":"Crossref","is-referenced-by-count":51,"title":["Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2\u2010year follow\u2010up study"],"prefix":"10.1111","volume":"77","author":[{"given":"Victoria","family":"Delgado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke R.","family":"Biermasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd W.","family":"van Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"See H.","family":"Ewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina Ajmone","family":"Marsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard R.","family":"Holman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Feelders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes W. A.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J.","family":"Bax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto M.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,6,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054830"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2010.00169.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0611"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)01064-9"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2658"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(86)90771-X"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.176857"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm095"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199809103391103"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068265"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2010.03827.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2095"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000255952.47980.c2"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc4101.097527"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(96)90440-8"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.90.2.844"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2011.04326.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2011.04326.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T20:51:11Z","timestamp":1698785471000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2011.04326.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,6]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1111\/j.1365-2265.2011.04326.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04326.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,6]]}}}